New Frontiers in Therapeutic Agents: Successes in Drugging the Undruggable

April 16-17, 2014

BioScience Research Collaborative
6500 Main Street, Houston, Texas 77030

Organizers: Kevin Dalby, Ph.D., The University of Texas at Austin, and
Philip Jones, Ph.D., The University of Texas MD Anderson Cancer Center

Significant advances in drugging difficult targets have been made in academic and industrial research centers, and numerous novel therapies are moving forward into clinical trials across different disease areas. The goal of this symposium is to provide illustrations of how these clinical agents have been developed and progressed into clinical trials. Examples will demonstrate how novel targets have been evaluated for druggability, how different approaches have been adopted to identify novel chemical matter, and steps leading to maturation of leads into novel therapeutic agents.

Keynote Speakers:
“RAS: The Elephant in the Room of Cancer Therapy”
- Garth Powis, Ph.D., Sanford Burnham Medical Research Institute

“Total Synthesis of Natural and Designed Molecules of Biological and Medical Importance”
- K.C. Nicolaou, Ph.D., Rice University

Additional invited speakers include:

Kevin Burgess, Ph.D., Texas A&M University
Kurt Deshayes, Ph.D., Genentech
Christopher Dinsmore, Ph.D., Forma Therapeutics
Scott Gilbertson, Ph.D., University of Houston
John MacMillan, University of Texas Southwestern
John McMurray, Ph.D., MD Anderson Cancer Center
Tamas Oravez, Ph.D. Lexicon Pharmaceuticals
Dafyd Owen, Ph.D., Pfizer

Jun Qi, Ph.D., Dana-Farber Cancer Institute
Ami Shah, Ph.D., GlaxoSmithKline
Robert Sims, Ph.D., Constellation Pharmaceuticals
Yongcheng Song, Ph.D., Baylor College of Medicine
Nicholas Terrett, Ph.D., Ensemble Therapeutics Corporation
Sharad Verma, Ph.D., GlaxoSmithKline
Sean Xie, Ph.D., University of Pittsburgh

Registration is complimentary.
Deadline: April 8, 2014

For registration and schedule, go to: http://www.txsact.org